Prosoria Scalp
Salicylic Acid
Nuvothera, Inc.
Human Otc Drug
NDC 71573-116Prosoria Scalp also known as Salicylic Acid is a human otc drug labeled by 'Nuvothera, Inc.'. National Drug Code (NDC) number for Prosoria Scalp is 71573-116. This drug is available in dosage form of Lotion/shampoo. The names of the active, medicinal ingredients in Prosoria Scalp drug includes Salicylic Acid - 1.33 g/74mL . The currest status of Prosoria Scalp drug is Active.
Drug Information:
| Drug NDC: | 71573-116 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Prosoria Scalp |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Salicylic Acid |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Nuvothera, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Lotion/shampoo |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SALICYLIC ACID - 1.33 g/74mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Apr, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part358H |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Nuvothera, Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 244525
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | O414PZ4LPZ
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 71573-116-09 | 74 mL in 1 BOTTLE, PLASTIC (71573-116-09) | 01 Apr, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose antipsoriasis, antiseborrheic
Product Elements:
Prosoria scalp salicylic acid salicylic acid salicylic acid water diethylene glycol monoethyl ether ammonium acryloyldimethyltaurate, dimethylacrylamide, lauryl methacrylate and laureth-4 methacrylate copolymer, trimethylolpropane triacrylate crosslinked (45000 mpa.s) tetrahydrodiferuloylmethane turmeric petrolatum oleth-3 phosphate edetate disodium anhydrous sodium hydroxide butylene glycol nigella sativa seed oil citric acid monohydrate .alpha.-tocopherol acetate polyisobutylene (1300 mw) betadex phenoxyethanol hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (100000 mpa.s at 1.5%) undecylenoyl glycine capryloyl glycine peg-7 trimethylolpropane coconut ether off white light yellow
Indications and Usage:
Uses relieves and helps prevent recurrence of symptoms of psoriasis and/or seborrheic dermatitis including: scaling flaking itching redness irritation
Warnings:
Warnings for external use only when using this product avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water. stop use and consult a doctor if the condition worsens or does not improve after regular use of this product as directed. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.
When Using:
When using this product avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water.
Dosage and Administration:
Directions apply and massage well on affected areas of the scalp once daily or as directed by a doctor. tip bottle and apply small drops to affected area of the scalp and spread evenly. let dry and leave on. shampoo hair when needed.
Stop Use:
Stop use and consult a doctor if the condition worsens or does not improve after regular use of this product as directed.
Package Label Principal Display Panel:
Principal display panel - 74 ml bottle label treats prosoriä scalp lotion 1.8% salicylic acid anti-psoriasis anti-seborrheic 2.5 fl oz (74ml) principal display panel - 74 ml bottle label
Further Questions:
Questions? visit www.prosoria.com or call toll-free 1-833-776-7483 mon â fri, 8am â 5pm ct.